Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and Losartan

被引:31
|
作者
Tobili, Jorge Eduardo [1 ]
Cao, Gabriel [1 ]
Lombrana, Alejandra [1 ]
Rivero, Miguel [1 ]
机构
[1] Hosp Aleman, Dept Internal Med, Expt Med Lab, RA-1118 Buenos Aires, DF, Argentina
来源
JOURNAL OF SEXUAL MEDICINE | 2007年 / 4卷 / 05期
关键词
erectile dysfunction; sildenafil; Losartan; combined therapy;
D O I
10.1111/j.1743-6109.2007.00567.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Erectile dysfunction (ED) is highly associated to cardiovascular disease, especially arterial hypertension. Phosphodiesterase type 5 (PDE5) inhibitors and angiotensin II receptor blockers (ARB) are both common and efficient therapy in patients with ED and arterial hypertension, respectively. Aim. To evaluate the effect of PDE5 inhibitor, sildenafil (S), and of ARB Losartan (L) in a continuous combined therapy for a long term on penile structures in a hypertensive rat model. Methods. During 6 months, four groups of male spontaneously hypertensive rats (SHR) and one of Wistar-Kyoto (WKY) rats, as control group, were studied: no-treatment SHR, SHR with L, SHR with S, SHR with S + L, and no-treatment WKY Cavernous smooth muscle (CSM) and vascular smooth muscle (VSM) from cavernous arteries, collagen type III (COL-III), and endothelial nitric oxide synthase (eNOS) expression in cavernous space were evaluated. Main Outcome Measure. Functional and morphological differences between S and L in a continuous combined therapy vs. either drug as monotherapy on penile structures. Results. After 6 months, SHR that received L, S, or combined therapy showed a similar reduction in blood pressure compared with untreated SHR. Nevertheless, SHR+L+S and control WXY showed significantly lower values of (i) CSM (P < 0.01), (ii) VSM (P < 0.01), and (iii) COL-III (P < 0.01) when compared with the untreated SHR and also with the SHR with monotherapy Additionally, SHR + L + S, presented a higher eNOS expression in sinusoidal endothelium in comparison with the untreated SHR and the SHR with monotherapy (P < 0.01). In vitro studies revealed that SHR + L + S displayed a better relaxation response to acetylcholine than the untreated SHR and the SHR with monotherapy (P < 0.01). Conclusion. These results suggest that a long-term combined therapy using L and S is a useful tool for functional and structural modification in cavernous tissue from SHR.
引用
收藏
页码:1291 / 1303
页数:13
相关论文
共 50 条
  • [1] Functional and morphological effects of long-term combined therapy with phosphodiesterase type 5 inhibitor and an angiotensin II receptor blocker in erectile tissue of hypertensive rats
    Toblli, J.
    Cao, G.
    Lombrana, A.
    Rivero, M.
    JOURNAL OF HYPERTENSION, 2007, 25 : S126 - S126
  • [2] Effects of chronic treatment with a Phosphodiesterase type 5 inhibitor on erectile function in spontaneously hypertensive rats
    Ahn, G. J.
    Kim, J. M.
    Kim, J. E.
    Choi, S. M.
    Kang, K. K.
    Ahn, B. O.
    Kim, J. W.
    Kim, W. B.
    Paick, J. S.
    JOURNAL OF SEXUAL MEDICINE, 2004, 1 : 63 - 63
  • [3] Phosphodiesterase type 5 inhibitor treatment of erectile dysfunction may impart long-term benefits for patients with depression
    Nurnberg, HG
    Siegel, R
    JOURNAL OF ANDROLOGY, 2005, : 73 - 73
  • [4] LONG-TERM PHOSPHODIESTERASE-5 INHIBITOR THERAPY PREVENTING PRIAPISM RECURRENCES
    Nardozza, Archimedes, Jr.
    Coelho, Mariana Andrade
    Oliveira, Frederico V.
    Kobaz, Alberto K.
    Alarcon, Gustavo
    Offerni, Juliano C. M.
    Cabrini, Marcelo R.
    Ortiz, Valdemar
    JOURNAL OF UROLOGY, 2009, 181 (04): : 528 - 529
  • [5] Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism
    Burnett, AL
    Bivalacqua, TJ
    Champion, HC
    Musicki, B
    UROLOGY, 2006, 67 (05) : 1043 - 1048
  • [6] MODIFICATION OF PRESSURE NATRIURESIS BY LONG-TERM LOSARTAN IN SPONTANEOUSLY HYPERTENSIVE RATS
    KLINE, RL
    LIU, F
    HYPERTENSION, 1994, 24 (04) : 467 - 473
  • [7] Long-term phosphodiesterase type 5 inhibitor therapy reduces priapic activity in transgenic sickle cell mice
    Bivalacqua, TJ
    Champion, HC
    Mason, W
    Burnett, AL
    JOURNAL OF UROLOGY, 2006, 175 (04): : 387 - 387
  • [8] Long-term oral phosphodiesterase-5 inhibitor therapy alleviates recurrent priapism
    Burnett, AL
    Bivalacqua, TJ
    Champion, HC
    Musicki, B
    JOURNAL OF UROLOGY, 2006, 175 (04): : 301 - 301
  • [9] Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
    Rosenberg, M. T.
    Adams, P. L.
    McBride, T. A.
    Roberts, J. N.
    McCallum, S. W.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) : 27 - 34
  • [10] FUNCTIONAL IMPROVEMENT WITH LONG-TERM LEVODOPA THERAPY
    GRAINGER, KM
    LANCET, 1973, 1 (7796): : 209 - 210